KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

SALAZOPYRIN TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

SULFASALAZINE

 

MANUFACTURER:

PHARMACIA & UPJOHN

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Colitis, ulcerative

 

SIDE EFFECTS:

Headache, continuing

hypersensitivity reaction

photosensitivity

serum sickness-like syndrome

Blood dyscrasias, including agranulocytosis or neutropenia

aplastic anemia

Heinz body or hemolytic anemia

leukopenia

thrombocytopenia

cyanosis

exacerbation of ulcerative colitis

hepatitis

interstitial pneumonitis

Stevens-Johnson syndrome

systemic lupus erythematosus (SLE)-like syndrome

toxic epidermal necrolysis

Gastrointestinal disturbances

Orange-yellow discoloration of urine or skin

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Allergy, severe

>> Asthma, bronchial

>> Blood dyscrasias

>> Glucose-6-phosphate dehydrogenase deficiency

>> Hepatic function impairment

>> Porphyria

>> Renal function impairment

 

ADULT DOSE:

Bowel disease (inflammatory) suppressant - Initial: Oral, 1 gram every six to eight hours. An initial dose of 500 mg every six to twelve hours may be recommended to lessen gastrointestinal side effects. Maintenance: Oral, 500 mg every six hours, adjusted according to patient response and tolerance. Antirheumatic (disease-modifying)- Oral, 500 mg to 1 gram daily for the first week, with the daily dose being increased by 500 mg each week, up to a maintenance dose of 2 grams daily. The dose may be administered two times a day. If no response is seen after two months, the dose may be increased to 3 grams daily.

 

MAXIMUM ADULT DOSE:

Total daily doses of greater than 4 grams may increase the risk of side effects and toxicity.

 

PEDIATRIC DOSE:

Bowel disease (inflammatory) suppressant - Infants and children up to 2 years of age- Use is contraindicated because sulfonamides may cause kernicterus. Children 2 years of age and older - Initial-Oral, 6.7 to 10 mg per kg of body weight every four hours; 10 to 15 mg per kg of body weight every six hours; or 13.3 to 20 mg per kg of body weight every eight hours. Maintenance-Oral, 7.5 mg per kg of body weight every six hours. Antirheumatic (disease-modifying)- Safety and efficacy have not been established. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Bowel disease (inflammatory) suppressant - Initial: Oral, 1 gram every six to eight hours. An initial dose of 500 mg every six to twelve hours may be recommended to lessen gastrointestinal side effects. Maintenance: Oral, 500 mg every six hours, adjusted according to patient response and tolerance. Antirheumatic (disease-modifying)- Oral, 500 mg to 1 gram daily for the first week, with the daily dose being increased by 500 mg each week, up to a maintenance dose of 2 grams daily. The dose may be administered two times a day. If no response is seen after two months, the dose may be increased to 3 grams daily.

 

 

PREVIOUS

  

NEXT